Supplementary Tables 1 - 19 from A Transcriptional and Metabolic Signature of Primary Aneuploidy Is Present in Chromosomally Unstable Cancer Cells and Informs Clinical Prognosis

XLSX file - 143K, Supplemental Table S1. GO terms enriched among genes correlated or anti-correlated with aneuploidy in MEFs. Supplemental Table S2. GO terms enriched among genes correlated or anti-correlated with karyotypic heterogeneity in cancer cell lines. Supplemental Table S3. GO terms enriched among genes correlated or anti-correlated with aneuploidy in MEFs, as determined by GSEA Supplemental Table S4. GO terms enriched among genes correlated or anti-correlated with karyotype heterogeneity in cancer cell lines, as determined by GSEA Supplemental Table S5. GO terms enriched among genes similarly affected by cancer and aneuploidy in primary cells. Supplemental Table S6. GO terms enriched among genes differentially affected by cancer and aneuploidy in primary cells. Supplemental Table S7. Enrichment of transcription factor motifs in the promoters of CIN-correlated genes. Table S8. GO terms enriched among genes correlated or anti-correlated with doubling time in cancer cell lines. Table S9. GO terms enriched among genes that are more strongly correlated or anti-correlated with CIN than with doubling time. Table S10. Metabolic pathways enriched among metabolites that are correlated or anti-correlated with karyotypic heterogeneity in cancer cell lines. Table S11. Metabolic pathways enriched among metabolites that are correlated or anti-correlated with doubling time in cancer cell lines. Supplemental Table S12. GO terms enriched among genes upregulated or downregulated by chromosome transfer into HCT-116 cells. Supplemental Table S13. Enrichment of transcription factor motifs in the promoters of genes upregulated or downregulated by chromosome transfer. Supplemental Table S14. The PCNA25 gene signature. Supplemental Table S15. The TRI70 gene signature. Table S16. The HET70 gene signature. Table S17. Stratification of patient risk by proliferation and aneuploidy-related gene signatures in published clinical cohorts. Table S18. Stratification of patient risk by the HET5 gene signature (training set). Table S19. Stratification of patient risk by the HET5 gene signature (test set).